On February 12, 2024, Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals Inc (VRTX, Financial), sold 1,738 shares of the company's stock, according to a recent SEC Filing. This transaction is part of the insider's trading activities, which over the past year have included a total of 1,738 shares sold and no shares purchased.
Vertex Pharmaceuticals Inc is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company is known for its focus on developing and commercializing therapies for the treatment of cystic fibrosis and advancing research and development programs in other areas of serious disease.
The insider transaction history for Vertex Pharmaceuticals Inc shows a pattern of insider sales over the past year, with 59 insider sells and no insider buys recorded.
On the date of the insider's recent sale, shares of Vertex Pharmaceuticals Inc were trading at $418.77, giving the company a market cap of $107.201 billion. The price-earnings ratio of the stock stands at 29.95, which is above both the industry median of 29.46 and the company's historical median price-earnings ratio.
According to the GuruFocus Value assessment, with a share price of $418.77 and a GF Value of $348.44, Vertex Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.2, indicating that the stock is considered Modestly Overvalued.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
